FindTrial
Sign In

Effectiveness of Acceptance and Commitment Therapy on death and health anxiety, cognitive and somatic symptoms of anxiety, and component of acceptance and commitment in patients with multiple sclerosis

Effectiveness of Acceptance and Commitment Therapy on death and health anxiety, cognitive and somatic symptoms of anxiety, and component of acceptance and commitment in patients with multiple sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017040833079N2
Enrollment
50
Registered
2017-05-02
Start date
2017-02-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: acceptance and commitment group therapy + routine medical treatment. Intervention 2: Control group: Routine medical treatment.
Behavior
Intervention group: acceptance and commitment group therapy + routine medical treatment
Control group: Routine medical treatment

Sponsors

Kashan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: being female; diagnosis of MS by a neurologist; satisfaction and commitment to participate in the study. Exclusion criteria: get interventions psychological treatment in the past year and the time of study; current mania or psychotic episode history of alcohol abuse or drugs; two sessions of absence for each patient.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Somatic Symptoms of anxiety. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: beck anxiety inventory (BAI).;Death anxiety. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: Death Anxiety Inventory.;Health anxiety. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: Health Anxiety Inventory.;Cognitive Symptoms of anxiety. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: Penn State Worry Questionnaire (PSWQ).;Cognitive fusion. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: cognitive fusion questionaire (CFQ).;Components of acceptance and commitment. Timepoint: Before intervention (baseline), after two month (post). Method of measurement: Acceptance and Action Questionnaire (AAQ-II).—

Secondary

MeasureTime frame
Therapeutic alliance. Timepoint: after intervention on experimental group. Method of measurement: Working Alliance Inventory-Short Revised (WAI-SR).;MS symptoms. Timepoint: Before intervention (baseline). Method of measurement: Multiple Sclerosis Impact Scale (MSIS-29).—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abdorreza Naser Moghadasi

MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences

abdorrezamoghadasi@gmail.com+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026